Stock MIST MILESTONE PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Milestone Pharmaceuticals Inc.

Equities

MIST

CA59935V1076

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
1.57 USD +1.95% Intraday chart for Milestone Pharmaceuticals Inc. -3.68% -5.99%
Apr. 08 Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients? Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting CI
Mar. 28 Milestone Pharmaceuticals Resubmits Etripamil New Drug Application to FDA MT

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Piper Sandler Trims Price Target on Milestone Pharmaceuticals to $5 From $6, Keeps Overweight Rating
MT
TD Cowen Cuts Price Target on Milestone Pharmaceuticals to $9 From $17, Maintains Outperform Rating
MT
Oppenheimer Adjusts Milestone Pharmaceuticals Price Target to $11 From $13, Maintains Outperform Rating
MT
Jefferies Downgrades Milestone Pharmaceuticals to Hold From Buy
MT
Oppenheimer Adjusts Milestone Pharmaceuticals' Price Target to $13 From $16, Keeps Outperform Rating
MT
Oppenheimer Adjusts Milestone Pharmaceuticals Price Target to $16 From $15, Maintains Outperform Rating
MT
Piper Sandler Lifts Milestone Pharmaceuticals to Overweight From Neutral, Price Target to $10 From $8
MT
MILESTONE PHARMACEUTICALS : Oppenheimer Adjusts Milestone Pharmaceuticals PT to $14 From $17, Maintains Outperform Rating
MT
MILESTONE PHARMACEUTICALS : Oppenheimer Adjusts Milestone Pharmaceuticals PT to $17 From $18 Following Q4 Report, Maintains Outperform Rating
MT
Milestone Pharmaceuticals : Enrolls First Patient in Phase 2 Trial of Etripamil in Atrial Fibrillation and Rapid Ventricular Rate
MT
Milestone Pharmaceuticals Announces First Patient Enrolled in the ReVeRA Study, its Phase 2 Trial of Etripamil in Atrial Fibrillation and Rapid Ventricular Rate
CI
MILESTONE PHARMACEUTICALS : HC Wainwright Starts Milestone Pharmaceuticals at Buy With $20 Price Target
MT
Milestone Pharmaceuticals : Enrolls First Patient in Phase 3 Study of Etripamil Nasal Spray for Rapid Heart Rate
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MIST Stock
  4. News Milestone Pharmaceuticals Inc.
  5. Analyst Reco.